---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-099708"
form_type: "8-K/A"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:40:00.799520+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Ironwood files audited VectivBio financials: 2022 net loss $94M, 2021 & 2022 restated

## Summary
- VectivBio 2022 revenue $27.3M from Asahi Kasei partner deal; net loss $94.1M.
- VectivBio held $221.4M cash at Dec 31, 2022; total assets $252.6M.
- Restated 2021 and 2022 statements to correct a misstatement; no further details here.
- Pro forma combined results for Ironwood + VectivBio for H1 2023 and FY2022 included in filing.

## SEC filing metadata
- accession: 0001104659-23-099708
- form_type: 8-K/A
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465923099708/0001104659-23-099708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465923099708/tm2325734d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-099708
- JSON: https://secwatch.observer/filing/0001104659-23-099708.json
- Plain text: https://secwatch.observer/filing/0001104659-23-099708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.